When the Supreme Court recently turned its attention to pharmaceutical pricing, it did not mince its words. Examining the enormous gap between the price of a life-saving cancer drug supplied to retailers at ₹2,700 and its maximum retail price (MRP) of ₹27,000, the Court described the situation as “absolute rampage and broad daylight dacoity”.

The remarks went beyond a complaint about excessive mark-ups. They exposed a policy deficit in a sector that affects the health and financial security of 1.4 billion people. The Court also highlighted gaps in the Drug Price Control Order (DPCO), under which many medicines remain outside scheduled ceiling-price regulation. The National Pharmaceutical Pricing Authority (NPPA) regulates prices under the existing framework, but the extent of its control remains a point of contention.

For policymakers, the challenge is to reconcile two competing priorities. India must protect patients from unaffordable medicines while building a pharmaceutical industry capable of developing innovative, patented drugs. The question is whether the country can pursue both goals through a more coherent regulatory framework, rather than treating affordability and innovation as opposing interests.

Pricing Divide
The regulatory structure reflects this tension. The Ministry of Health approaches pharmaceuticals primarily through patient access, disease management and affordability. The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, focuses more directly on industrial growth, investment and exports.

These priorities are not inherently incompatible, but fragmented policymaking can make them difficult to reconcile. The NPPA must balance affordability with the need to maintain medicine availability and a viable manufacturing base. Meanwhile, the government’s Jan Aushadhi programme has sought to improve access by offering generic medicines at discounted prices. The challenge is to extend affordability without creating uncertainty over the commercial conditions needed to sustain supply and investment.

The debate over branded medicines brings these tensions into sharper focus. Two industry bodies represent different, though not mutually exclusive, approaches to India’s pharmaceutical future.

The Indian Pharmaceutical Alliance (IPA) represents major domestic, research-based pharmaceutical companies with a substantial presence in the generic medicines market. According to the IPA, its members account for more than 80% of India’s pharmaceutical exports and over 64% of the domestic market. The alliance argues that affordable medicines, reliable supply chains and a competitive manufacturing base must remain central to policy. It has also called for pricing and regulatory arrangements that allow companies to invest in research and develop new therapies.

The concern is that excessive price pressure, particularly when it pushes prices below sustainable levels, could weaken incentives to invest in manufacturing capacity and quality. From this perspective, price regulation must protect patients without undermining the availability of essential medicines.

The Organisation of Pharmaceutical Producers of India (OPPI), which represents research-based multinational pharmaceutical companies, emphasises the economics of drug discovery. Developing a new medicine requires substantial investment, lengthy research and clinical trials, with no guarantee of success. Global innovators argue that unpredictable pricing policies and uncertainty over intellectual property rights (IPR) can discourage the introduction of patented therapies in India.

Their argument is that India cannot become a major centre for pharmaceutical innovation if companies have little confidence in the commercial returns available from successful drug discovery. But that case does not settle the question of what patients should pay, or how much public support should be used to make high-cost treatments accessible.

Both groups want India to become a global pharmaceutical powerhouse, but their priorities differ. Domestic manufacturers emphasise scale, affordability and competitiveness in generics. Multinational innovators place greater weight on intellectual property protection and the returns required to fund research. The policy challenge is to accommodate these interests without allowing either industry profitability or patient affordability to become the sole measure of success.

Innovation Path
India has established itself as a major supplier of generic medicines, but its presence in novel drug discovery remains more limited. Moving into higher-value pharmaceutical research will require greater investment in scientific capabilities, clinical research and technology, alongside a predictable framework for patents and pricing.

Trade partners, particularly the United States, have also pressed India to strengthen intellectual property protection and improve market access for innovative medicines. These pressures add to the case for a clearer policy framework, but they do not remove the government’s responsibility to ensure that essential treatments remain accessible.

A structural reform of pharmaceutical governance could help. Drug pricing, quality regulation, intellectual property policy and industrial promotion need better coordination, even if their statutory responsibilities remain with separate institutions. A unified policy framework would provide clearer objectives, reduce conflicting signals and make regulatory decisions more predictable for manufacturers and patients alike.

India should also consider a more differentiated approach to pricing.

For mature, off-patent essential medicines, transparent price regulation and effective monitoring of trade margins can help prevent excessive mark-ups and protect patients. The aim should be to ensure that affordable medicines remain available, not simply to push prices down regardless of the effect on supply. Competition from quality-assured generics, stronger procurement systems and public disclosure of prices can reinforce this approach.

Innovative and patented medicines require a different assessment. Pricing flexibility and credible intellectual property protection can support investment, but neither should mean an unconditional guarantee of high prices. Where public funding, local manufacturing commitments or technology transfer are part of the arrangement, the terms should be clearly defined and linked to measurable outcomes.

For expensive treatments, including advanced biologics, rare-disease therapies and newer cancer drugs, blunt price controls may not always be the most effective instrument. The government could expand negotiated procurement, risk-sharing agreements and tiered pricing with manufacturers. Such arrangements can link payment to patient access, treatment outcomes or agreed volumes, while allowing the state to negotiate lower prices for publicly funded care.

The objective should be to make high-cost treatments more accessible while giving innovators a clearer route to recover research and development costs. That requires transparent negotiations, safeguards against excessive pricing and reliable mechanisms to ensure that agreed savings reach patients.

The Supreme Court’s observations have brought the consequences of weak pricing oversight into sharp relief. But the answer cannot be a choice between corporate returns and public health. Nor can India expect to become a pharmaceutical innovation hub while treating the economics of drug discovery as irrelevant.

India needs a regulatory framework that recognises two obligations: medicines must be affordable to the people who need them, and the pharmaceutical ecosystem must remain capable of producing the next generation of treatments. A coherent policy that combines targeted price controls, stronger competition, negotiated access to expensive drugs and predictable innovation incentives would offer a more sustainable path than treating these goals as mutually exclusive.